Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
BUSINESS Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
-
REGULATORY Antivirals, Cancer Drugs Flagged in PMDA Risk Review
January 19, 2026
-
BUSINESS 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
-
BUSINESS Nobelpharma Launches Pediatric Sleep Aid Melatonin in China
January 19, 2026
-
REGULATORY Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
-
REGULATORY Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…